[Retracted] Time Intervals between Double Primary Breast and Ovarian Cancers and Survival Outcomes of Patients with Both Cancers: A SEER Database Analysis
Table 1
Demographic and clinicopathological characteristics of patients with primary BC and primary OC stratified by tumor sequence and time intervals between both cancers.
Variables
BC to OC Group 1
Synchronous Group 2
OC to BC Group 3
value
Overall
Total, (%)
2,929 (58.9%)
680 (13.7%)
1,366 (27.5%)
4,975
Age (median, range) at BC diagnosis
59 (23–93)
64 (28–98)
66 (22–97)
<0.05
62 (22–98)
Age (median, range) at OC diagnosis
67 (25–98)
64 (28–98)
57 (10–90)
<0.05
64 (10–98)
Race
0.008
White
2,372 (81.0%)
526 (77.4%)
1,118 (81.8%)
4,016 (80.7%)
Black
154 (5.3%)
61 (9.0%)
76 (5.9%)
291 (5.8%)
Hispanic
213 (7.3%)
52 (7.6%)
84 (6.1%)
349 (7.0%)
Asian/Pacific islander
176 (6.0%)
35 (5.1%)
84 (6.1%)
295 (5.9%)
Other
14 (0.5%)
6 (0.9%)
4 (0.3%)
24 (0.5%)
OC distribution by year
<0.001
1973–1982
94 (3.2%)
67(9.9%)
245 (17.9%)
406 (8.2%)
1983–1992
349 (11.9%)
84(12.4%)
267 (19.5%)
700 (14.1%)
1993–2002
704 (24.0%)
172 (25.3%)
414 (30.3%)
1,290 (25.9%)
2003–2015
1,782 (60.8%)
357 (52.5%)
440 (32.2%)
2,579 (51.8%)
BC distribution by year
<0.001
1973–1982
439 (15.0%)
67 (9.9%)
57 (4.2%)
563 (11.3%)
1983–1992
613 (20.9%)
85 (12.5%)
164 (12.0%)
862 (17.3%)
1993–2002
1,099 (37.5%)
171 (25.1%)
285 (20.9%)
1,555 (31.3%)
2003–2015
778 (26.6%)
357 (52.5%)
860 (63.0%)
1,995 (40.1%)
OC grade
<0.001
Grade I
99 (3.4%)
46 (6.8%)
156 (11.4%)
301 (6.1%)
Grade II
304 (10.4%)
78 (11.5%)
241 (17.6%)
623 (12.5%)
Grade III
1,013 (34.6%)
201 (29.6%)
432 (31.6%)
1,646 (33.1%)
Grade IV
435 (14.9%)
67 (9.9%)
127 (9.3%)
629 (12.6%)
Unknown
1,078 (36.8%)
288 (42.4%)
410 (30.0%)
1,776 (35.7%)
OC stage (2004–2015)
1663
339
382
<0.001
2,384
I
238 (14.3%)
71 (20.9%)
133 (34.8%)
442 (18.5%)
II
144 (8.7%)
26 (7.7%)
49 (12.8%)
219 (9.2%)
III
658 (39.6%)
120 (35.4%)
120 (31.4%)
898 (37.7%)
IV
436 (26.2%)
83 (24.5%)
62 (16.2%)
581 (24.4%)
Unknown
187 (11.2%)
39 (11.5%)
18 (4.7%)
244 (10.2%)
OC pathologic type
<0.001
Serous
1,354 (46.2%)
294 (43.2%)
510 (37.3%)
2,158 (43.4%)
Mucinous
109 (3.7%)
38 (5.6%)
155 (11.3%)
302 (6.1%)
Clear cell
111(3.8%)
28 (4.1%)
85 (6.2%)
224 (4.5%)
Endometrioid
193 (6.6%)
49 (7.2%)
227 (16.6%)
469 (9.4%)
Other
1,162 (39.7%)
271 (39.9%)
389 (28.5%)
1,822 (36.6%)
BC grade
<0.001
Grade I
364 (12.4%)
102 (15.0%)
215 (15.7%)
681 (13.7%)
Grade II
715 (24.4%)
172 (25.3%)
451 (33.0%)
1,338 (26.9%)
Grade III
883 (30.1%)
197 (29.0%)
435 (31.8%)
1,515 (30.5%)
Grade IV
83 (2.8%)
11 (1.6%)
16 (1.2%)
110 (2.2%)
Unknown
884 (30.2%)
198 (29.1%)
249 (18.2%)
1,331 (26.8%)
BC stage (1988–2015)#
2,218
566
1,235
<0.001
4,019
I
1,100 (49.6%)
191 (33.7%)
625 (50.6%)
1,916 (47.7%)
II
710 (32.0%)
157 (27.7%)
343 (27.8%)
1,210 (30.1%)
III
214 (9.6%)
53 (9.4%)
109 (8.8%)
376 (9.4%)
IV
34 (1.5%)
69 (12.2%)
54 (4.4%)
157 (3.9%)
Other
160 (7.2%)
96 (17.0%)
104 (8.4%)
360 (9.0%)
BC pathologic type
0.096
Infiltrating ductal carcinoma
2,091 (71.4%)
458 (67.4%)
976 (71.4%)
3,525 (70.9%)
Other
838 (28.6%)
222 (32.6%)
390 (28.6%)
1,450 (29.1%)
Interval (median, range), in months
75 (7–499)
73 (7–496)
60 (0–499)
Note: Ovarian cancer stage derived from AJCC 6th Stage (2004+); #breast cancer stage adjusted for AJCC 6th Stage (1988+); OC: ovarian cancer; BC: breast cancer.
